Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVOLUTION MEDICINES, INC.

(RVMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

09/15/2021 | 07:31am EDT

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference’s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company’s development-stage KRASG12C(ON) inhibitor, will each deliver a scientific presentation as part of the conference.

Details of Revolution Medicines’ participation in the 3rd Annual RAS-Targeted Drug Development Summit are as follows:

Presentations:
  
Title:Targeting KRASG12C(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors
Presenter:Bob Nichols, Ph.D., project lead for RMC-6291
Date:Wednesday, September 22, 2021
Time:11:55 a.m. Eastern
  
Title:Combination Strategies to Defeat RAS-Addicted Cancers
Presenter:Jan Smith, Ph.D., senior vice president, biology
Date:Wednesday, September 22, 2021
Time:2:00 p.m. Eastern
  
Panel Discussion:
  
Title:On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510
Moderator:Steve Kelsey, M.D., president, research and development
Date:Thursday, September 23, 2021
Time:4:15 p.m. Eastern
  
Scientific Track:
  
Title:Validating Robust Combination Strategies
Chairperson:Steve Kelsey, M.D., president, research and development
Date/Time:Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern
Thursday, September 23, 2021; 11:00 a.m. – 12:30 p.m. Eastern
  

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdevelopment.com/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Contacts:

For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401
sdiaz@vidasp.com

For Media:
Vida Strategic Partners
Tim Brons
415-675-7402
tbrons@vidasp.com


Primary Logo


ę GlobeNewswire 2021
All news about REVOLUTION MEDICINES, INC.
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
09/30REVOLUTION MEDICINES : to Present New Preclinical Data from RAS(ON) Inhibitor Programs at ..
GL
09/23REVOLUTION MEDICINES : Stifel Starts Revolution Medicines at Hold With $34 Price Target
MT
09/22REVOLUTION MEDICINES : Combination Strategies to Defeat RAS-Addicted Cancers
PU
09/22REVOLUTION MEDICINES : Targeting KRAS-G12C(ON) and Potential Application to Overcoming Dru..
PU
09/15Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
GL
09/07Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Confer..
GL
09/06GLOBAL MARKETS LIVE : Puma, Boeing, Holcim, Revolut, Amazon...
08/17REVOLUTION MEDICINES : HC Wainwright Adjusts Revolution Medicines' Price Target to $31 Fro..
MT
More news
Analyst Recommendations on REVOLUTION MEDICINES, INC.
More recommendations
Financials (USD)
Sales 2021 36,0 M - -
Net income 2021 -176 M - -
Net cash 2021 316 M - -
P/E ratio 2021 -11,4x
Yield 2021 -
Capitalization 2 030 M 2 030 M -
EV / Sales 2021 47,6x
EV / Sales 2022 42,5x
Nbr of Employees 150
Free-Float 98,8%
Chart REVOLUTION MEDICINES, INC.
Duration : Period :
Revolution Medicines, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVOLUTION MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 27,59 $
Average target price 33,17 $
Spread / Average Target 20,2%
EPS Revisions
Managers and Directors
Mark A. Goldsmith Chairman, President & Chief Executive Officer
Jack Anders Principal Financial & Accounting Officer
Stephen M. Kelsey President-Research & Development
Walter Reiher Chief Information Officer
Xiaolin Wang Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
REVOLUTION MEDICINES, INC.-31.47%1 996
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-39.00%26 036